This webpage is designed to be viewed on a laptop screen or larger.
Dysport® injections may be repeated approximately every 16 weeks, or as required to maintain a response, but not more frequently than every 12 weeks.1
Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex)
Efficacy information
In an open-label extension study, the mean time to retreatment was 15–17 weeks over repeat cycles.2
Mean time to retreatment over repeated cycles (n=108)15(±5.6)-17(±8.0) WEEKS OVER THREE OPEN-LABEL CYCLES |
82% of patients did not require reinjection at week 12, with more than 40% not requiring reinjection at week 16.3
Dysport® may allow your patients to find lasting symptom relief between injections.2,3
Figure adapted from Esquenazi A, et al. 2020.3
In an open-label prospective study, Dysport® improved quality of life and pain intensity.4
Dysport® is the only BoNT-A with a Level A recommendation (the highest quality of evidence for efficacy) for cervical dystonia by the AAN5,6
| Indication | Level of recommendation‡ | |||
|---|---|---|---|---|
| Level A | Level B | Level C | Level U | |
| Cervical dystonia | Dysport® | OnabotulinumtoxinA IncobotulinumtoxinA |
Table adapted from AAN Guidelines.6
*Statistically significant (P<0.001) vs baseline.
†Statistically significant (P<0.001) vs baseline change from baseline score was worse at weeks 12 to 4.
‡Level A: established as effective, or useful; should be offered.6 Level B: probably effective, or probably useful; should be considered.6 Level C: possibly effective, or possibly useful; may be considered.6 Level U: data inadequate or conflicting; insufficient to support or refute a benefit.6
References:
- Dysport® Summary of Product Characteristics.
- Truong D, et al. Parkinsonism Relat Disord. 2010;16:316–323.
- Esquenazi A, et al. Front Neurol. 2020;11:576117.
- Hefter H, et al. BMJ Open. 2013;3(4):e001853.
- Simpson DM, et al. Neurology. 2016;86(19):1818–1826.
- Practice Guideline Update: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache. Available at: https://www.aan.com/Guidelines/home/GetGuidelineContent/738 (Accessed: September 2025).
Abbreviations:
AAN, American Academy of Neurology; BoNT-A, BoNT-A, botulinum toxin type A; CD, cervical dystonia; CDQ-24, Craniocervical Dystonia Questionnaire; QoL, quality of life; VAS, visual analogue scale.
For further information, please refer to the Prescribing Information or the Summary of Product Characteristics.